Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information

(3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid

EU orphan designation number: EU/3/05/278   
Active ingredient: (3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid
Indication: Treatment of Duchenne muscular dystrophy
Sponsor: PTC Therapeutics, Limited
16 Great Queen Street, Covent Garden, London WC2B 5AH, United Kingdom

   Public summary of scientific opinion    


European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
31/05/2005 Centralised Orphan - Designation EMEA/OD/106/04 (2005)1655 of 27/05/2005
22/05/2007 Centralised Orphan - Transfer of orphan designation EMEA/OD/106/04/T/01 (2007)2144 of 14/05/2007
26/04/2012 Centralised Orphan - Transfer of orphan designation EMEA/OD/106/04/T/02 (2012)2898 of 23/04/2012
02/08/2013 Other procedure